Drug Discovery Services Market by Process (Target Validation, Hit-to-Lead, Lead Optimization), Type (Chemistry, Biology), Therapeutic Area (Oncology, Neurology, Infectious, CVD), Drug Type (Small Molecules, Biologics), End User - Global Forecast to 2030
The global drug discovery services market is anticipated to reach USD 27.23 billion in 2030 from USD 16.36 billion in 2025, with a significant CAGR of 10.7%. The market is growing strongly at a considerable CAGR due to rising R&D investments of pharmaceutical and biopharmaceutical firms. As the pipeline of R&D expands, the requirement for outsourcing analytical testing is set to rise, in addition to the research initiatives on the rare diseases and orphan drugs. Furthermore, the high costs of in-house drug development have also contributed to this trend. Industry players are likely to witness healthy growth opportunities due to the technological advancement, new drug discovery techniques, patent expiry, and rising demand for specialized testing services among end users.
“Chemistry services dominated the type segment”
Based on type, the drug discovery services market is divided into chemistry services, and biology services. The chemistry services segment is further divided into synthetic chemistry services, analytical chemistry services, other chemistry services. The development of technologies like combinatorial chemistry and structure-based drug design has contributed to the growth of chemistry services. Chemistry’s extensive use in drug discovery particularly for lead molecule identification, lead modification or optimization, scale-up of the optimized lead for further drug development processes, and efficacy testing, has contributed to the growing demand for the segment.
“The hit-to-lead identification dominated the process segment”
Based on process, the drug discovery services market includes target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. The hit-to-lead identification services dominated the market. Growth in the hit-to-lead identification services market is predetermined due to its crucial place in drug discovery, being the maximum revenue-generating process. Many CROs offer these services to pharmaceutical companies. Moreover, key players are focusing on improving this critical step of drug discovery.
“The small molecules dominated the drug type segment”
Based on drug type, the drug discovery services market can be segmented into small molecules, and biologics. Small molecules would hold largest share in the market. The increasing growth of the small molecules can be attributed to several factors such as ease of working with, low costs, and increasing startup and new entrants focusing on small-molecule drug development. Small molecules can also easily enter the cells thanks to their low molecular weights. They may act on other molecules and kill cancer cells. As such, small molecules or small-molecule inhibitors are used extensively for many targeted therapies.
“Cardiovascular diseases segment is anticipated to grow at a great pace”
The therapeutic area segment is divided into oncology, infectious diseases, cardiovascular diseases, neurological diseases, immunological disorders, endocrine & metabolic disorders, respiratory disorders, digestive system diseases, genitourinary diseases & women's health, and other therapeutic areas. The market for cardiovascular diseases is dominated due to high prevalence of cardiovascular diseases, rising geriatric population, and increasing partnerships between CROs and pharmaceutical & biotechnology companies. The integration of genetic and personalized medicine innovations will also support the growth of cardiovascular disease therapeutic discovery and development.
“Pharmaceutical & Biotechnology Companies dominated the segment”
Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, academic institutes, and other end users. Pharmaceutical & biotechnology companies dominated the segment in 2024. The largest share of pharmaceutical and biotechnology companies in the drug discovery services market is due to the growing R&D expenditure for new molecules development, the increasing outsourcing of clinical services by these companies, and a strong pipeline of biotechnology companies to increase profit margins and reduce the time of drug development.
“US to grow at the highest CAGR for North America drug discovery services market”
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the drug discovery services market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of key players. The country’s focus on R&D expenditure, and rapid growth in the biosimilar and biologics markets further boosts its leadership in the market. European drug discovery services market is experiencing steady growth, supported by demographic changes, the growing prevalence of diseases, and investments in R&D.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the drug discovery services market.
The primary interviews conducted for this report can be categorized as follows:
Research Coverage:
Drug discovery services market report is segmented based on process (target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation), by type [(chemistry services (synthetic chemistry services, analytical chemistry services, other chemistry services), and biology services (in vitro profiling services, toxicology services, and other biology services)], by drug type (small molecules, and biologics), by therapeutic area (oncology, infectious diseases, cardiovascular diseases, neurological diseases, immunological disorders, endocrine & metabolic disorders, respiratory disorders, digestive system diseases, genitourinary diseases & women's health, and other therapeutic areas), by end user (pharmaceutical & biotechnology companies, academic institutes, and other end users), and region (North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the high content screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the high content screening market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the drug discovery services and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
“Chemistry services dominated the type segment”
Based on type, the drug discovery services market is divided into chemistry services, and biology services. The chemistry services segment is further divided into synthetic chemistry services, analytical chemistry services, other chemistry services. The development of technologies like combinatorial chemistry and structure-based drug design has contributed to the growth of chemistry services. Chemistry’s extensive use in drug discovery particularly for lead molecule identification, lead modification or optimization, scale-up of the optimized lead for further drug development processes, and efficacy testing, has contributed to the growing demand for the segment.
“The hit-to-lead identification dominated the process segment”
Based on process, the drug discovery services market includes target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. The hit-to-lead identification services dominated the market. Growth in the hit-to-lead identification services market is predetermined due to its crucial place in drug discovery, being the maximum revenue-generating process. Many CROs offer these services to pharmaceutical companies. Moreover, key players are focusing on improving this critical step of drug discovery.
“The small molecules dominated the drug type segment”
Based on drug type, the drug discovery services market can be segmented into small molecules, and biologics. Small molecules would hold largest share in the market. The increasing growth of the small molecules can be attributed to several factors such as ease of working with, low costs, and increasing startup and new entrants focusing on small-molecule drug development. Small molecules can also easily enter the cells thanks to their low molecular weights. They may act on other molecules and kill cancer cells. As such, small molecules or small-molecule inhibitors are used extensively for many targeted therapies.
“Cardiovascular diseases segment is anticipated to grow at a great pace”
The therapeutic area segment is divided into oncology, infectious diseases, cardiovascular diseases, neurological diseases, immunological disorders, endocrine & metabolic disorders, respiratory disorders, digestive system diseases, genitourinary diseases & women's health, and other therapeutic areas. The market for cardiovascular diseases is dominated due to high prevalence of cardiovascular diseases, rising geriatric population, and increasing partnerships between CROs and pharmaceutical & biotechnology companies. The integration of genetic and personalized medicine innovations will also support the growth of cardiovascular disease therapeutic discovery and development.
“Pharmaceutical & Biotechnology Companies dominated the segment”
Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, academic institutes, and other end users. Pharmaceutical & biotechnology companies dominated the segment in 2024. The largest share of pharmaceutical and biotechnology companies in the drug discovery services market is due to the growing R&D expenditure for new molecules development, the increasing outsourcing of clinical services by these companies, and a strong pipeline of biotechnology companies to increase profit margins and reduce the time of drug development.
“US to grow at the highest CAGR for North America drug discovery services market”
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the drug discovery services market in 2024 and is estimated to continue dominance during the forecast period. US leads the North American market, driven by the presence of key players. The country’s focus on R&D expenditure, and rapid growth in the biosimilar and biologics markets further boosts its leadership in the market. European drug discovery services market is experiencing steady growth, supported by demographic changes, the growing prevalence of diseases, and investments in R&D.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the drug discovery services market.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 – 55%, Tier 2 – 25%, and Tier 3 – 20%
- By Designation: Directors - 45%, Managers - 30%, and Others - 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
Research Coverage:
Drug discovery services market report is segmented based on process (target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation), by type [(chemistry services (synthetic chemistry services, analytical chemistry services, other chemistry services), and biology services (in vitro profiling services, toxicology services, and other biology services)], by drug type (small molecules, and biologics), by therapeutic area (oncology, infectious diseases, cardiovascular diseases, neurological diseases, immunological disorders, endocrine & metabolic disorders, respiratory disorders, digestive system diseases, genitourinary diseases & women's health, and other therapeutic areas), by end user (pharmaceutical & biotechnology companies, academic institutes, and other end users), and region (North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the high content screening market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the high content screening market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the drug discovery services and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, Increasing demand for outsourcing analytical testing services, Initiatives for research on rare diseases and orphan drugs, High cost of in-house drug development), restraints (Stringent regulations governing drug discovery and animal usages), opportunities (Growth in drugs and biologics market, Rising demand for specialized testing services among end users, Patent Expiry, High growth prospect in emerging markets) and Challenges (Economic uncertainties worldwide) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on upcoming technologies in drug discovery services, research and development activities, and new service launches in the drug discovery services market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the drug discovery services market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi AppTec (China), and Pharmaron (China), and Labcorp (US), among others.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Objectives of primary research
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET ESTIMATION
2.2.2 SEGMENTAL MARKET ESTIMATION
2.3 GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW
4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET,
BY DRUG TYPE AND COUNTRY, 2024
4.3 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 DRUG DISCOVERY SERVICES MARKET, BY END USER
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Booming research & development expenditure in
pharma-biotech sector
5.2.1.2 Growing pipeline of pharmaceutical and biopharmaceutical companies
5.2.1.3 Rising research on rare diseases and orphan drugs
5.2.1.4 Increasing reliance on outsourcing due to costly in-house drug development
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulations
5.2.3 OPPORTUNITIES
5.2.3.1 Technological advancements and new drug discovery techniques
5.2.3.2 Rising demand for specialized testing services
5.2.3.3 Patent expiry of key biologics
5.2.3.4 High growth prospects in emerging markets
5.2.4 CHALLENGES
5.2.4.1 Economic uncertainties worldwide
5.2.5 MARKET TRENDS
5.2.5.1 Adoption of AI in drug discovery
5.2.5.2 Increased outsourcing in emerging economies
5.2.5.3 Consolidation of contract research organizations
5.2.5.4 Integrated end-to-end R&D service offerings
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY TYPE
5.4.2 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY REGION
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 High-throughput screening
5.9.1.2 CRISPR gene editing
5.9.1.3 Structure-based drug design/Computer-aided drug design
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Automated liquid handling
5.9.2.2 In silico modeling
5.9.2.3 Patient-derived xenografts and organoids
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Nanotechnology
5.9.3.2 Synthetic biology
5.9.3.3 Organ-on-a-chip technology
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES AND EVENTS, 2025–2026
5.12 REGULATORY LANDSCAPE
5.12.1 REGULATORY FRAMEWORK
5.12.1.1 North America
5.12.1.1.1 US
5.12.1.1.2 Canada
5.12.1.2 Europe
5.12.1.2.1 UK
5.12.1.3 Asia Pacific
5.12.1.3.1 China
5.12.1.3.2 Japan
5.12.1.3.3 India
5.12.1.3.4 South Korea
5.12.1.3.5 Australia
5.12.1.3.6 Rest of Asia Pacific
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 BARGAINING POWER OF SUPPLIERS
5.13.2 BARGAINING POWER OF BUYERS
5.13.3 THREAT OF NEW ENTRANTS
5.13.4 THREAT OF SUBSTITUTES
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 KEY BUYING CRITERIA, BY END USER
5.15 IMPACT OF AI ON DRUG DISCOVERY SERVICES MARKET
5.15.1 INTRODUCTION
5.15.2 MARKET POTENTIAL OF AI IN DRUG DISCOVERY SERVICES
5.15.3 AI USE CASES
5.15.4 FUTURE OF GENERATIVE AI IN DRUG DISCOVERY SERVICES MARKET
6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS
6.1 INTRODUCTION
6.2 TARGET SELECTION
6.2.1 INCREASING FOCUS ON IDENTIFYING POTENTIAL DRUG TARGETS TO BOLSTER GROWTH
6.3 TARGET VALIDATION
6.3.1 INCREASING EMPHASIS ON AVOIDING LATE-STAGE FAILURE TO PROMOTE GROWTH
6.4 HIT-TO-LEAD IDENTIFICATION
6.4.1 RISING FOCUS ON DRUG DEVELOPMENT TO DRIVE MARKET
6.5 LEAD OPTIMIZATION
6.5.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS IN CLINICAL TRIALS TO STIMULATE GROWTH
6.6 CANDIDATE VALIDATION
6.6.1 GROWING ATTENTION ON POTENCY AND SPECIFICITY OF DRUGS TO BOOST MARKET
7 DRUG DISCOVERY SERVICES MARKET, BY TYPE
7.1 INTRODUCTION
7.2 CHEMISTRY SERVICES
7.2.1 SYNTHETIC CHEMISTRY SERVICES
7.2.1.1 Increasing reliance on novel and efficient synthetic routes to augment growth
7.2.2 ANALYTICAL CHEMISTRY SERVICES
7.2.2.1 Rising demand for high-quality, safe, and effective drugs to support growth
7.2.3 OTHER CHEMISTRY SERVICES
7.3 BIOLOGY SERVICES
7.3.1 IN VITRO PROFILING SERVICES
7.3.1.1 Need for higher project productivity to speed up growth
7.3.2 TOXICOLOGY SERVICES
7.3.2.1 Growing emphasis on assessing safety profiles of new drug candidates to propel market
7.3.3 OTHER BIOLOGY SERVICES
8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE
8.1 INTRODUCTION
8.2 SMALL MOLECULES
8.2.1 INCREASING FOCUS ON OPTIMIZING SMALL-MOLECULE LEADS TO AMPLIFY GROWTH
8.3 BIOLOGICS
8.3.1 GROWING ADVANCEMENTS IN BIOTECHNOLOGY TO BOOST MARKET
9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA
9.1 INTRODUCTION
9.2 ONCOLOGY
9.2.1 GROWING INCIDENCE OF CANCER TO PROPEL MARKET
9.3 INFECTIOUS DISEASES
9.3.1 RISING EPIDEMIC OUTBREAKS TO ASSIST GROWTH
9.4 CARDIOVASCULAR DISEASES
9.4.1 HIGH MORTALITY RATES TO SPUR GROWTH
9.5 NEUROLOGICAL DISEASES
9.5.1 INCREASING RESEARCH & DEVELOPMENT INVESTMENTS FOR NEUROLOGICAL DISORDERS TO FAVOR GROWTH
9.6 IMMUNOLOGICAL DISORDERS
9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO BOOST MARKET
9.7 ENDOCRINE & METABOLIC DISORDERS
9.7.1 BOOMING DIABETIC POPULATION TO AID GROWTH
9.8 RESPIRATORY DISORDERS
9.8.1 RISING BURDEN OF RESPIRATORY DISORDERS TO SUPPORT GROWTH
9.9 DIGESTIVE SYSTEM DISEASES
9.9.1 CHANGING LIFESTYLE AND DIETARY HABITS TO PROMOTE GROWTH
9.10 GENITOURINARY DISEASES & WOMEN’S HEALTH
9.10.1 RISING AWARENESS ABOUT EARLY DIAGNOSIS AND TREATMENT TO SUSTAIN GROWTH
9.11 OTHER THERAPEUTIC AREAS
10 DRUG DISCOVERY SERVICES MARKET, BY END USER
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 TIER 1 COMPANIES
10.2.1.1 Rising research & development activities to sustain growth
10.2.2 TIER 2 COMPANIES
10.2.2.1 Growing focus on specific therapeutic areas to drive market
10.2.3 TIER 3 COMPANIES
10.2.3.1 Increasing specialized drug discovery projects to expedite growth
10.3 ACADEMIC INSTITUTES
10.3.1 INCREASING COLLABORATIONS AMONG MARKET PLAYERS TO CONTRIBUTE TO GROWTH
10.4 OTHER END USERS
11 DRUG DISCOVERY SERVICES MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
11.2.2 US
11.2.2.1 Global leadership in pharmaceutical and biopharmaceutical research to aid growth
11.2.3 CANADA
11.2.3.1 Increasing initiatives for commercializing drugs to stimulate growth
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK OF EUROPE
11.3.2 GERMANY
11.3.2.1 Rising dominance of contract research organizations to encourage growth
11.3.3 UK
11.3.3.1 Increasing government-private sector collaborations to boost market
11.3.4 FRANCE
11.3.4.1 Growing number of oncology research projects to propel market
11.3.5 ITALY
11.3.5.1 High number of clinical trials and low drug approval time to promote growth
11.3.6 SPAIN
11.3.6.1 Rising elderly population to intensify growth
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK OF ASIA PACIFIC
11.4.2 CHINA
11.4.2.1 Booming pharmaceutical industry to sustain growth
11.4.3 JAPAN
11.4.3.1 Increasing geriatric population to support growth
11.4.4 INDIA
11.4.4.1 Growing foreign direct investments to drive market
11.4.5 SOUTH KOREA
11.4.5.1 Favorable government support to accelerate growth
11.4.6 AUSTRALIA
11.4.6.1 Rising number of clinical trials to foster growth
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK OF LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Reduced timeline for drug approvals to favor growth
11.5.3 MEXICO
11.5.3.1 Favorable government policies to intensify growth
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
11.6.2 GCC COUNTRIES
11.6.2.1 Saudi Arabia
11.6.2.1.1 Booming healthcare expenditure to contribute to growth
11.6.2.2 UAE
11.6.2.2.1 Rising government initiatives for advanced healthcare to amplify growth
11.6.2.3 Other GCC Countries
11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
11.7.1 RISING BURDEN OF CANCER AND CHRONIC DISEASES TO FACILITATE GROWTH
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET
12.3 REVENUE ANALYSIS, 2020?2024
12.4 MARKET SHARE ANALYSIS, 2024
12.5 COMPANY VALUATION AND FINANCIAL METRICS
12.6 BRAND/SERVICE COMPARISON
12.6.1 THERMO FISHER SCIENTIFIC INC. (US)
12.6.2 CHARLES RIVER LABORATORIES (US)
12.6.3 LABCORP (US)
12.6.4 WUXI APPTEC (CHINA)
12.6.5 PHARMARON (CHINA)
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.7.1 STARS
12.7.2 EMERGING LEADERS
12.7.3 PERVASIVE PLAYERS
12.7.4 PARTICIPANTS
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.7.5.1 Company footprint
12.7.5.2 Region footprint
12.7.5.3 Process footprint
12.7.5.4 Type footprint
12.7.5.5 Therapeutic area footprint
12.7.5.6 Drug type footprint
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.8.1 PROGRESSIVE COMPANIES
12.8.2 RESPONSIVE COMPANIES
12.8.3 DYNAMIC COMPANIES
12.8.4 STARTING BLOCKS
12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
12.8.5.1 Detailed list of key startups/SMEs
12.8.5.2 Competitive benchmarking of key startups/SMEs
12.9 COMPETITIVE SCENARIO
12.9.1 SERVICE LAUNCHES
12.9.2 DEALS
12.9.3 EXPANSIONS
12.9.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 THERMO FISHER SCIENTIFIC INC.
13.1.1.1 Business overview
13.1.1.2 Services offered
13.1.1.3 Recent developments
13.1.1.3.1 Service launches
13.1.1.3.2 Deals
13.1.1.3.3 Expansions
13.1.1.4 MnM view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 CHARLES RIVER LABORATORIES
13.1.2.1 Business overview
13.1.2.2 Services offered
13.1.2.3 Recent developments
13.1.2.3.1 Service launches
13.1.2.3.2 Deals
13.1.2.4 MnM view
13.1.2.4.1 Key strengths
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses and competitive threats
13.1.3 WUXI APPTEC
13.1.3.1 Business overview
13.1.3.2 Services offered
13.1.3.3 Recent developments
13.1.3.3.1 Expansions
13.1.3.4 MnM view
13.1.3.4.1 Key strengths
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 PHARMARON
13.1.4.1 Business overview
13.1.4.2 Services offered
13.1.4.2.1 Deals
13.1.4.3 MnM view
13.1.4.3.1 Key strengths
13.1.4.3.2 Strategic choices
13.1.4.3.3 Weaknesses and competitive threats
13.1.5 LABCORP
13.1.5.1 Business overview
13.1.5.2 Services offered
13.1.5.3 Recent developments
13.1.5.3.1 Deals
13.1.5.3.2 Expansions
13.1.5.4 MnM view
13.1.5.4.1 Key strengths
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses and competitive threats
13.1.6 EVOTEC
13.1.6.1 Business overview
13.1.6.2 Services offered
13.1.6.3 Recent developments
13.1.6.3.1 Deals
13.1.6.3.2 Expansions
13.1.6.3.3 Other developments
13.1.7 SYNGENE INTERNATIONAL LIMITED
13.1.7.1 Business overview
13.1.7.2 Services offered
13.1.7.3 Recent developments
13.1.7.3.1 Deals
13.1.7.3.2 Expansions
13.1.8 EUROFINS SCIENTIFIC
13.1.8.1 Business overview
13.1.8.2 Services offered
13.1.8.3 Recent developments
13.1.8.3.1 Service launches
13.1.8.3.2 Deals
13.1.8.3.3 Expansions
13.1.9 JUBILANT PHARMOVA LIMITED
13.1.9.1 Business overview
13.1.9.2 Services offered
13.1.9.3 Recent developments
13.1.9.3.1 Deals
13.1.9.3.2 Expansions
13.1.10 GENSCRIPT
13.1.10.1 Business overview
13.1.10.2 Services offered
13.1.10.3 Recent developments
13.1.10.3.1 Service launches
13.1.10.3.2 Deals
13.1.11 FRONTAGE HOLDINGS CORPORATION
13.1.11.1 Business overview
13.1.11.2 Services offered
13.1.11.3 Recent developments
13.1.11.3.1 Service launches
13.1.11.3.2 Deals
13.1.11.3.3 Expansions
13.1.12 PIRAMAL ENTERPRISES LTD.
13.1.12.1 Business overview
13.1.12.2 Services offered
13.1.12.3 Recent developments
13.1.12.3.1 Expansions
13.1.13 AURIGENE PHARMACEUTICAL SERVICES LTD.
13.1.13.1 Business overview
13.1.13.2 Services offered
13.1.13.3 Recent developments
13.1.13.3.1 Service launches
13.1.13.3.2 Deals
13.1.13.3.3 Expansions
13.1.14 CURIA GLOBAL, INC.
13.1.14.1 Business overview
13.1.14.2 Services offered
13.1.14.3 Recent developments
13.1.14.3.1 Service launches
13.1.14.3.2 Deals
13.1.14.3.3 Other developments
13.1.15 SHANGHAI MEDICILON INC.
13.1.15.1 Business overview
13.1.15.2 Services offered
13.1.15.3 Recent developments
13.1.15.3.1 Deals
13.1.15.3.2 Expansions
13.1.16 SYGNATURE DISCOVERY
13.1.16.1 Business overview
13.1.16.2 Services offered
13.1.16.2.1 Deals
13.1.16.2.2 Expansions
13.2 OTHER PLAYERS
13.2.1 SELVITA
13.2.2 VIVA BIOTECH
13.2.3 TCG LIFESCIENCES PVT. LTD.
13.2.4 SHANGHAI CHEMPARTNER
13.2.5 DOMAINEX
13.2.6 NUVISAN GMBH
13.2.7 DALTON PHARMA SERVICES
13.2.8 ARAGEN LIFE SCIENCES LTD.
13.2.9 ONCODESIGN SERVICES
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Objectives of primary research
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET ESTIMATION
2.2.2 SEGMENTAL MARKET ESTIMATION
2.3 GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW
4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET,
BY DRUG TYPE AND COUNTRY, 2024
4.3 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 DRUG DISCOVERY SERVICES MARKET, BY END USER
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Booming research & development expenditure in
pharma-biotech sector
5.2.1.2 Growing pipeline of pharmaceutical and biopharmaceutical companies
5.2.1.3 Rising research on rare diseases and orphan drugs
5.2.1.4 Increasing reliance on outsourcing due to costly in-house drug development
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulations
5.2.3 OPPORTUNITIES
5.2.3.1 Technological advancements and new drug discovery techniques
5.2.3.2 Rising demand for specialized testing services
5.2.3.3 Patent expiry of key biologics
5.2.3.4 High growth prospects in emerging markets
5.2.4 CHALLENGES
5.2.4.1 Economic uncertainties worldwide
5.2.5 MARKET TRENDS
5.2.5.1 Adoption of AI in drug discovery
5.2.5.2 Increased outsourcing in emerging economies
5.2.5.3 Consolidation of contract research organizations
5.2.5.4 Integrated end-to-end R&D service offerings
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY TYPE
5.4.2 INDICATIVE PRICING ANALYSIS OF DRUG DISCOVERY SERVICES, BY REGION
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 High-throughput screening
5.9.1.2 CRISPR gene editing
5.9.1.3 Structure-based drug design/Computer-aided drug design
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Automated liquid handling
5.9.2.2 In silico modeling
5.9.2.3 Patient-derived xenografts and organoids
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Nanotechnology
5.9.3.2 Synthetic biology
5.9.3.3 Organ-on-a-chip technology
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES AND EVENTS, 2025–2026
5.12 REGULATORY LANDSCAPE
5.12.1 REGULATORY FRAMEWORK
5.12.1.1 North America
5.12.1.1.1 US
5.12.1.1.2 Canada
5.12.1.2 Europe
5.12.1.2.1 UK
5.12.1.3 Asia Pacific
5.12.1.3.1 China
5.12.1.3.2 Japan
5.12.1.3.3 India
5.12.1.3.4 South Korea
5.12.1.3.5 Australia
5.12.1.3.6 Rest of Asia Pacific
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 BARGAINING POWER OF SUPPLIERS
5.13.2 BARGAINING POWER OF BUYERS
5.13.3 THREAT OF NEW ENTRANTS
5.13.4 THREAT OF SUBSTITUTES
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 KEY BUYING CRITERIA, BY END USER
5.15 IMPACT OF AI ON DRUG DISCOVERY SERVICES MARKET
5.15.1 INTRODUCTION
5.15.2 MARKET POTENTIAL OF AI IN DRUG DISCOVERY SERVICES
5.15.3 AI USE CASES
5.15.4 FUTURE OF GENERATIVE AI IN DRUG DISCOVERY SERVICES MARKET
6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS
6.1 INTRODUCTION
6.2 TARGET SELECTION
6.2.1 INCREASING FOCUS ON IDENTIFYING POTENTIAL DRUG TARGETS TO BOLSTER GROWTH
6.3 TARGET VALIDATION
6.3.1 INCREASING EMPHASIS ON AVOIDING LATE-STAGE FAILURE TO PROMOTE GROWTH
6.4 HIT-TO-LEAD IDENTIFICATION
6.4.1 RISING FOCUS ON DRUG DEVELOPMENT TO DRIVE MARKET
6.5 LEAD OPTIMIZATION
6.5.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS IN CLINICAL TRIALS TO STIMULATE GROWTH
6.6 CANDIDATE VALIDATION
6.6.1 GROWING ATTENTION ON POTENCY AND SPECIFICITY OF DRUGS TO BOOST MARKET
7 DRUG DISCOVERY SERVICES MARKET, BY TYPE
7.1 INTRODUCTION
7.2 CHEMISTRY SERVICES
7.2.1 SYNTHETIC CHEMISTRY SERVICES
7.2.1.1 Increasing reliance on novel and efficient synthetic routes to augment growth
7.2.2 ANALYTICAL CHEMISTRY SERVICES
7.2.2.1 Rising demand for high-quality, safe, and effective drugs to support growth
7.2.3 OTHER CHEMISTRY SERVICES
7.3 BIOLOGY SERVICES
7.3.1 IN VITRO PROFILING SERVICES
7.3.1.1 Need for higher project productivity to speed up growth
7.3.2 TOXICOLOGY SERVICES
7.3.2.1 Growing emphasis on assessing safety profiles of new drug candidates to propel market
7.3.3 OTHER BIOLOGY SERVICES
8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE
8.1 INTRODUCTION
8.2 SMALL MOLECULES
8.2.1 INCREASING FOCUS ON OPTIMIZING SMALL-MOLECULE LEADS TO AMPLIFY GROWTH
8.3 BIOLOGICS
8.3.1 GROWING ADVANCEMENTS IN BIOTECHNOLOGY TO BOOST MARKET
9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA
9.1 INTRODUCTION
9.2 ONCOLOGY
9.2.1 GROWING INCIDENCE OF CANCER TO PROPEL MARKET
9.3 INFECTIOUS DISEASES
9.3.1 RISING EPIDEMIC OUTBREAKS TO ASSIST GROWTH
9.4 CARDIOVASCULAR DISEASES
9.4.1 HIGH MORTALITY RATES TO SPUR GROWTH
9.5 NEUROLOGICAL DISEASES
9.5.1 INCREASING RESEARCH & DEVELOPMENT INVESTMENTS FOR NEUROLOGICAL DISORDERS TO FAVOR GROWTH
9.6 IMMUNOLOGICAL DISORDERS
9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO BOOST MARKET
9.7 ENDOCRINE & METABOLIC DISORDERS
9.7.1 BOOMING DIABETIC POPULATION TO AID GROWTH
9.8 RESPIRATORY DISORDERS
9.8.1 RISING BURDEN OF RESPIRATORY DISORDERS TO SUPPORT GROWTH
9.9 DIGESTIVE SYSTEM DISEASES
9.9.1 CHANGING LIFESTYLE AND DIETARY HABITS TO PROMOTE GROWTH
9.10 GENITOURINARY DISEASES & WOMEN’S HEALTH
9.10.1 RISING AWARENESS ABOUT EARLY DIAGNOSIS AND TREATMENT TO SUSTAIN GROWTH
9.11 OTHER THERAPEUTIC AREAS
10 DRUG DISCOVERY SERVICES MARKET, BY END USER
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 TIER 1 COMPANIES
10.2.1.1 Rising research & development activities to sustain growth
10.2.2 TIER 2 COMPANIES
10.2.2.1 Growing focus on specific therapeutic areas to drive market
10.2.3 TIER 3 COMPANIES
10.2.3.1 Increasing specialized drug discovery projects to expedite growth
10.3 ACADEMIC INSTITUTES
10.3.1 INCREASING COLLABORATIONS AMONG MARKET PLAYERS TO CONTRIBUTE TO GROWTH
10.4 OTHER END USERS
11 DRUG DISCOVERY SERVICES MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
11.2.2 US
11.2.2.1 Global leadership in pharmaceutical and biopharmaceutical research to aid growth
11.2.3 CANADA
11.2.3.1 Increasing initiatives for commercializing drugs to stimulate growth
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK OF EUROPE
11.3.2 GERMANY
11.3.2.1 Rising dominance of contract research organizations to encourage growth
11.3.3 UK
11.3.3.1 Increasing government-private sector collaborations to boost market
11.3.4 FRANCE
11.3.4.1 Growing number of oncology research projects to propel market
11.3.5 ITALY
11.3.5.1 High number of clinical trials and low drug approval time to promote growth
11.3.6 SPAIN
11.3.6.1 Rising elderly population to intensify growth
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK OF ASIA PACIFIC
11.4.2 CHINA
11.4.2.1 Booming pharmaceutical industry to sustain growth
11.4.3 JAPAN
11.4.3.1 Increasing geriatric population to support growth
11.4.4 INDIA
11.4.4.1 Growing foreign direct investments to drive market
11.4.5 SOUTH KOREA
11.4.5.1 Favorable government support to accelerate growth
11.4.6 AUSTRALIA
11.4.6.1 Rising number of clinical trials to foster growth
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK OF LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Reduced timeline for drug approvals to favor growth
11.5.3 MEXICO
11.5.3.1 Favorable government policies to intensify growth
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
11.6.2 GCC COUNTRIES
11.6.2.1 Saudi Arabia
11.6.2.1.1 Booming healthcare expenditure to contribute to growth
11.6.2.2 UAE
11.6.2.2.1 Rising government initiatives for advanced healthcare to amplify growth
11.6.2.3 Other GCC Countries
11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
11.7.1 RISING BURDEN OF CANCER AND CHRONIC DISEASES TO FACILITATE GROWTH
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY SERVICES MARKET
12.3 REVENUE ANALYSIS, 2020?2024
12.4 MARKET SHARE ANALYSIS, 2024
12.5 COMPANY VALUATION AND FINANCIAL METRICS
12.6 BRAND/SERVICE COMPARISON
12.6.1 THERMO FISHER SCIENTIFIC INC. (US)
12.6.2 CHARLES RIVER LABORATORIES (US)
12.6.3 LABCORP (US)
12.6.4 WUXI APPTEC (CHINA)
12.6.5 PHARMARON (CHINA)
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.7.1 STARS
12.7.2 EMERGING LEADERS
12.7.3 PERVASIVE PLAYERS
12.7.4 PARTICIPANTS
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.7.5.1 Company footprint
12.7.5.2 Region footprint
12.7.5.3 Process footprint
12.7.5.4 Type footprint
12.7.5.5 Therapeutic area footprint
12.7.5.6 Drug type footprint
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.8.1 PROGRESSIVE COMPANIES
12.8.2 RESPONSIVE COMPANIES
12.8.3 DYNAMIC COMPANIES
12.8.4 STARTING BLOCKS
12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
12.8.5.1 Detailed list of key startups/SMEs
12.8.5.2 Competitive benchmarking of key startups/SMEs
12.9 COMPETITIVE SCENARIO
12.9.1 SERVICE LAUNCHES
12.9.2 DEALS
12.9.3 EXPANSIONS
12.9.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 THERMO FISHER SCIENTIFIC INC.
13.1.1.1 Business overview
13.1.1.2 Services offered
13.1.1.3 Recent developments
13.1.1.3.1 Service launches
13.1.1.3.2 Deals
13.1.1.3.3 Expansions
13.1.1.4 MnM view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 CHARLES RIVER LABORATORIES
13.1.2.1 Business overview
13.1.2.2 Services offered
13.1.2.3 Recent developments
13.1.2.3.1 Service launches
13.1.2.3.2 Deals
13.1.2.4 MnM view
13.1.2.4.1 Key strengths
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses and competitive threats
13.1.3 WUXI APPTEC
13.1.3.1 Business overview
13.1.3.2 Services offered
13.1.3.3 Recent developments
13.1.3.3.1 Expansions
13.1.3.4 MnM view
13.1.3.4.1 Key strengths
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 PHARMARON
13.1.4.1 Business overview
13.1.4.2 Services offered
13.1.4.2.1 Deals
13.1.4.3 MnM view
13.1.4.3.1 Key strengths
13.1.4.3.2 Strategic choices
13.1.4.3.3 Weaknesses and competitive threats
13.1.5 LABCORP
13.1.5.1 Business overview
13.1.5.2 Services offered
13.1.5.3 Recent developments
13.1.5.3.1 Deals
13.1.5.3.2 Expansions
13.1.5.4 MnM view
13.1.5.4.1 Key strengths
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses and competitive threats
13.1.6 EVOTEC
13.1.6.1 Business overview
13.1.6.2 Services offered
13.1.6.3 Recent developments
13.1.6.3.1 Deals
13.1.6.3.2 Expansions
13.1.6.3.3 Other developments
13.1.7 SYNGENE INTERNATIONAL LIMITED
13.1.7.1 Business overview
13.1.7.2 Services offered
13.1.7.3 Recent developments
13.1.7.3.1 Deals
13.1.7.3.2 Expansions
13.1.8 EUROFINS SCIENTIFIC
13.1.8.1 Business overview
13.1.8.2 Services offered
13.1.8.3 Recent developments
13.1.8.3.1 Service launches
13.1.8.3.2 Deals
13.1.8.3.3 Expansions
13.1.9 JUBILANT PHARMOVA LIMITED
13.1.9.1 Business overview
13.1.9.2 Services offered
13.1.9.3 Recent developments
13.1.9.3.1 Deals
13.1.9.3.2 Expansions
13.1.10 GENSCRIPT
13.1.10.1 Business overview
13.1.10.2 Services offered
13.1.10.3 Recent developments
13.1.10.3.1 Service launches
13.1.10.3.2 Deals
13.1.11 FRONTAGE HOLDINGS CORPORATION
13.1.11.1 Business overview
13.1.11.2 Services offered
13.1.11.3 Recent developments
13.1.11.3.1 Service launches
13.1.11.3.2 Deals
13.1.11.3.3 Expansions
13.1.12 PIRAMAL ENTERPRISES LTD.
13.1.12.1 Business overview
13.1.12.2 Services offered
13.1.12.3 Recent developments
13.1.12.3.1 Expansions
13.1.13 AURIGENE PHARMACEUTICAL SERVICES LTD.
13.1.13.1 Business overview
13.1.13.2 Services offered
13.1.13.3 Recent developments
13.1.13.3.1 Service launches
13.1.13.3.2 Deals
13.1.13.3.3 Expansions
13.1.14 CURIA GLOBAL, INC.
13.1.14.1 Business overview
13.1.14.2 Services offered
13.1.14.3 Recent developments
13.1.14.3.1 Service launches
13.1.14.3.2 Deals
13.1.14.3.3 Other developments
13.1.15 SHANGHAI MEDICILON INC.
13.1.15.1 Business overview
13.1.15.2 Services offered
13.1.15.3 Recent developments
13.1.15.3.1 Deals
13.1.15.3.2 Expansions
13.1.16 SYGNATURE DISCOVERY
13.1.16.1 Business overview
13.1.16.2 Services offered
13.1.16.2.1 Deals
13.1.16.2.2 Expansions
13.2 OTHER PLAYERS
13.2.1 SELVITA
13.2.2 VIVA BIOTECH
13.2.3 TCG LIFESCIENCES PVT. LTD.
13.2.4 SHANGHAI CHEMPARTNER
13.2.5 DOMAINEX
13.2.6 NUVISAN GMBH
13.2.7 DALTON PHARMA SERVICES
13.2.8 ARAGEN LIFE SCIENCES LTD.
13.2.9 ONCODESIGN SERVICES
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
